

Central Lancashire Online Knowledge (CLOK)

Title	Adverse Effects of Excessive Zinc Intake in Infants and Children Aged 0-3 Years: A Systematic Review and Meta-Analysis
Type	Article
URL	https://clock.uclan.ac.uk/43825/
DOI	https://doi.org/10.1093/advances/nmac088
Date	2022
Citation	Ceballos Rasgado, Marena, Lowe, Nicola M, Mallard, Simonette, Clegg, Andrew, Moran, Victoria H, Harris, Catherine orcid iconORCID: 0000-0001-7763-830X, Montez, Jason and Xipsiti, Maria (2022) Adverse Effects of Excessive Zinc Intake in Infants and Children Aged 0-3 Years: A Systematic Review and Meta-Analysis. <i>Advances in Nutrition</i> .
Creators	Ceballos Rasgado, Marena, Lowe, Nicola M, Mallard, Simonette, Clegg, Andrew, Moran, Victoria H, Harris, Catherine, Montez, Jason and Xipsiti, Maria

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1093/advances/nmac088>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

Adverse effects of excessive zinc intake in infants and children aged 0-3 years: A systematic review and meta-analysis

Marena Ceballos-Rasgado^a, Nicola M Lowe^{a*}, Simonette Mallard^b, Andrew Clegg^c, Victoria H Moran^a, Catherine Harris^c, Jason Montez^d, Maria Xipsiti^e.

^a Centre for Global Development, University of Central Lancashire, Preston, United Kingdom

^b Independent contractor, Dunedin, New Zealand

^c Synthesis, Economic Evaluation and Decision Science (SEEDS) Group, Applied Health Research Hub, University of Central Lancashire, Preston, United Kingdom.

^d Department of Nutrition and Food Safety, World Health Organization (WHO), Geneva, Switzerland

^e Food and Nutrition Division, Food and Agriculture Organization of the United Nations (FAO), Rome, Italy

For Advances in Nutrition:

The Authors declare that there is no conflict of interest

This systematic review, funded by FAO and WHO

*Professor Nicola M Lowe, Director of the UCLan Research Centre for Global Development

Faculty of Allied Health and Wellbeing, University of Central Lancashire, Preston UK.

Email: nmlowe@UCLan.ac.uk

Abstract

Zinc supplementation reduces morbidity, but evidence suggests that excessive intakes may have negative health consequences. Current guidelines of upper limits (ULs) of zinc intake for young children are extrapolated from adult data. This systematic review (PROSPERO; registration no. CRD42020215187) aimed to determine the levels of zinc intake at which adverse effects are observed in young children. Studies reporting potential adverse effects of zinc intake in children aged 0-3 years were identified (from inception to August 2020) in MEDLINE, EMBASE and the Cochrane Library, with no limits on study design. Adverse clinical and physical effects of zinc intake were synthesized narratively, and meta-analyses of biochemical outcomes were conducted. Random effects models, forest plots were generated to examine the evidence by age category, dose, dose duration, chemical formula of zinc, and zinc vs placebo. The Joanna Briggs Institute Critical Appraisal Checklist, Cochrane Risk of Bias 2, and Grading of Recommendations Assessment, Development and Evaluation guideline (GRADE) were employed to assess risk of bias and to appraise the certainty of evidence. Fifty-eight studies assessed possible adverse effects of zinc doses ranging from 3 to 70 mg/d. Data from 39 studies contributed to meta-analyses. Zinc supplementation had an adverse effect on serum ferritin, plasma/serum copper concentration, sTfR, hemoglobin, hematocrit, and the odds of anemia in at least one of the subgroups investigated. Lactulose:mannitol ratio was improved with zinc supplementation, and no significant effect was observed on CRP, eSOD, ZPP and blood cholesterol and iron deficiency anemia. The certainty of the evidence, as assessed using GRADE, was very low to moderate. Although possible adverse effects of zinc supplementation were observed in some subgroups, it is unclear whether these findings are clinically important. The synthesized data can be used to undertake a dose-response analysis to update current guidelines of ULs of zinc intake for young children.

Key words: Zinc, dietary requirements, children, upper limits, systematic review, meta-analysis

Statement of significance

This systematic review and meta-analysis was commissioned by the FAO-WHO, and aimed to synthesize the available evidence to answer clearly defined questions posed by the FAO-WHO expert group, regarding zinc intake in relation to needs for growth (tissue composition), excretion, absorption, and factors affecting bioavailability in children aged 0-3 years. Findings of this review may be a valuable resource for future national and international organizations looking to update or adapt dietary guidelines for infants and children.

Introduction

The Upper Limits (ULs) of nutrient intakes have been defined as the maximum intake from food, water and supplements that is unlikely to pose risk of adverse health effects to most individuals in the general population (1). This information is particularly valuable when designing large-scale supplementation or fortification programs to ensure that the resulting nutrient intakes do not exceed a value that is considered safe for human health. ULs are determined through a risk assessment process which assesses the probability of the occurrence of an adverse health effect from an excess exposure to the nutrient (2). This process requires the collection of information of known or potential adverse effects attributed to the nutrient, followed by a dose-response analysis to determine the relationship between the dose of the nutrient and adverse effect on key outcome measures (3). For most nutrients no adverse effects are anticipated when they are consumed as foods because their absorption and/or excretion are regulated through homeostatic mechanisms (1). This is the case for zinc, where absorption and excretion are adjusted over a wide range of dietary intakes (4). In

addition, zinc is not stored in body tissues, thus the potential for zinc to reach toxic levels is limited. However, if zinc is ingested in excessive amounts or in smaller amounts but on a chronic basis through supplementation, it is associated with deleterious alterations in iron, copper lipoprotein and cholesterol metabolism (3), and adverse physiological effects including nausea, vomiting and general gastrointestinal disturbances (3,5).

The current Food and Agriculture Organization (FAO) - World Health Organization (WHO) values for zinc ULs are 35-50 mg/day (690 μ mol/day) for adults, and 23–28 mg/day (350-430 μ mol/day) for children depending on their age (1). In setting these ULs, a dose response analysis for children was not possible due to a lack of data, therefore the ULs for children in various age categories were extrapolated from adult data based on basal metabolic rate (1,3). An alternative strategy was adopted when considering zinc ULs by expert groups convened by the Institute of Medicine (IOM)(6) and International Zinc Nutrition Consultative Group (IZiNCG)(7). Both groups used data from a small number of studies conducted in children relating to the impact of zinc intake on copper status. IZiNCG concluded that there were insufficient data to define ULs for children and instead published a “No Observed Adverse Effect Level” (NOAEL) value of 6-26 mg/day depending on the age of the child. The IOM identified a NOAEL value and divided it by an uncertainty factor which considered the length of exposure and the number of infants included in the one study (8). After obtaining values for young infants, the IOM adjusted the ULs for older infants and children on the basis of relative body weight to produce a recommendation of 4 mg/day for infants 0-6 months, 5-mg/day for infants 7-12 months and 7 mg/day for children 1-3 years (6).

FAO-WHO has convened an expert group to update their vitamin and mineral requirements and ULs of intake for micronutrients in children aged 0-3 years (9), and commissioned this review to inform the work of updating the ULs for zinc in this age group. The aim of this

review was to determine the levels of zinc intake at which adverse effects are observed in children aged 0-3 years

Methods

Protocol and registration

This systematic review was registered with the international Prospective Register of Systematic Reviews (PROSPERO; registration no. CRD42020215187) and was conducted following the PRISMA-2020 statement for reporting systematic reviews and meta-analyses (10).

Eligibility Criteria

Eligibility criteria are based on the Population, Intervention, Comparison, Outcomes and Study (PICOS) elements. Criteria were identified through discussion with the expert group and shown in **Table 1**.

Search Strategy, Study Selection and Data Extraction

The search was carried out using Medline (OVID), Embase (OVID), Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library) from date of inception to 7th August 2020. The searches had no date nor language restriction. The initial search strategy is presented in **Supplementary file 1** and comprised terms related to zinc, adverse effects toxicity and outcomes known to be potentially affected by excess zinc. As a preceding scoping review indicated a lack of studies investigating excess zinc intake among children aged 0-3 years, the search was not limited by age. However, for the purposes of this manuscript, only studies that included children aged 0-3 years will be reported.

The search results were downloaded into Endnote software for automatic and manual deduplication and then exported into the Rayyan web app (11) where one reviewer (MCR) screened for inclusion and exclusion by title and abstract. The articles were flagged when there was uncertainty, and discussions for their inclusion or exclusion took place with senior members of the review team (NML, VHM). Hand-searches were conducted by examining the reference lists of the retrieved articles, and relevant systematic reviews. Articles potentially meeting inclusion criteria and those that remained uncertain were moved forward to the next stage, where one reviewer (SM) screened the full text. At each stage of screening, a randomly selected 10% of articles were cross-checked by a second member of the review team (NML, VHM or MCR). Any disagreement was resolved by discussion and changes made accordingly.

Due to the broad range of outcome measures reported by a small number of studies, the search strategy was adjusted to include studies that did not have terms related to toxicity and adverse effects in the title and abstract. The expanded search strategy is shown in

Supplementary file 1. The purpose of this expanded search was to capture studies that measured relevant outcomes without the presupposition of toxicity, thus increasing the number of included studies, particularly at the lower zinc dose/exposure rates. The expanded search results were de-duplicated against the original search and screened for inclusion and exclusion as described above (**Supplementary file 1**).

Data extraction and synthesis

One reviewer (SM) extracted the data from the included articles into a specifically designed Excel form, and a randomly selected sample (10%) of extracted articles was cross-checked by a member of the review team (MCR). Data extracted included bibliographic information, location, aim, study methods, population characteristics, type of exposures to zinc (the type of exposure, duration of exposure, amount of zinc exposed to), outcomes (adverse event or

obtained from a systematic review on
form the work of updating requirements
y assessed from complementary foods,
y food zinc intake. These age-matched
review , to provide a total dietary zinc
cluded children 0-3 years and where the
comparable arm without zinc). Where
age category [0-90 days, 91-180 days,
d, 5-10 mg/d, 10.1-20mg/d, >20 mg/d,
months), chemical formula of zinc
placebo, and high vs low dose of zinc.
ormation about the population

[illegible]

characteristics, zinc exposure, and the presence of a
FAO-WHO expert group
drowsiness, mouth irritation
standard way of reporting

Statistical Analysis

Meta-analyses were conducted using RevMan (Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2014). Where outcomes were presented as continuous data, they were synthesized as weighted mean differences with 95% confidence intervals (CI) using the generic inverse-variance method. Dichotomous data were pooled as odds ratios (OR) with 95% CI through the Mantel-Haenszel method. Given the likelihood of variability among the studies, we estimated random-effects models. Heterogeneity was assessed through visual inspection of forest plots and through the χ^2 and I^2 statistic, with possible causes investigated through sub-group and sensitivity analyses. Publication bias was assessed using funnel plots for comparisons of 10 or more studies (15), with the causes of asymmetry judged in relation to non-reporting bias, methodological quality, heterogeneity and artefactual reasons. Where appropriate, GRADE assessment was adjusted to reflect any bias identified.

Assessment of Risk of Bias

Cochrane Risk of Bias 2 (RoB) was used to assess the quality of all randomized controlled trials (RCTs) (16). Four trials were classified as 'quasi-experimental' rather than RCT (8,17–19) because details of the randomization process were not made explicit, although all had elements of random allocation and all were double blind. In two studies participants were allocated into groups based on successive age sequence (8,18) and in two studies methods of allocation were not adequately described (17,19). Therefore these studies were deemed acceptable for inclusion in meta-analyses by consensus and were assessed using Cochrane RoB. Two case studies (20,21) were assessed using the Joanna Briggs Institute (JBI) Appraisal checklist (22). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) (23) system was used to evaluate the certainty of evidence of all outcomes included in meta-analyses. As all studies included in meta-analyses had been assessed using Cochrane RoB, the initial level of certainty for GRADE was high (24).

Reasons for considering lowering the level of certainty included risk of bias, inconsistency, indirectness (such as the population having an underlying health condition), imprecision and publication bias (25). Raising the level of certainty was not considered as this is generally used for observational studies only (24).

Results

Description of studies

From the studies retrieved by the initial electronic search (N=7,158), hand searches (N=90), and the expanded search (N=15), 316 potentially relevant studies were assessed for inclusion once the full-text reports had been obtained. From these, 180 papers were excluded on a full-text basis and the reasons for exclusion are shown in the PRISMA diagram in **Figure 1**. A total of 136 articles were considered relevant across all population groups (N=58 infants and children aged 0-3 years, N= 18 children aged >3 years, and N=53 adults). As the evidence available on infants and children aged 0-3 years was sufficient to avoid extrapolation from data on older children and adults, this paper focusses only on 58 articles from 55 studies (8,12,13,17–21,26–75) that investigated possible adverse effects of excess of zinc intake in infants and children aged 0-3 years. A complete list of biochemical outcome measures and physical and clinical descriptive outcomes included in these studies are given in **Table 2**. (Detailed information on study design can be found in **Table 1 of the supplementary file 2**).

Two articles, Hess et al. (43) and Sazawal et al. (63), were the same study of Abbeddou et al. (74) and Olney et al. (53) respectively, but reported additional data, therefore both studies were included in this review. Two papers that reported on the same study but measured outcomes at different timepoints following zinc supplementation (Muñoz et al. (52) at 6 months and Rosado et al. (59) at 12 months) were included in the review, but only data from Rosado et al. (59) was considered for meta-analyses.

Almost all included studies were RCTs (N=53) (12,13,18,26–75) and three were quasi-experimental (8,17,19).

Daily doses of zinc ranged from 3 mg/d to 45 mg/d, from zinc supplementation or fortification. Six studies (8,19,34,48,50,72) administered doses below 5 mg/d, 34 studies (in 36 articles) (12,13,17,26,29–31,35–43,47,51,53–56,60–65,68–75) reported administering doses of 5 to 10 mg/d, ten studies (in 11 articles) (28,44,46,49,52,56–59,67,69) reported the effects of doses between 10.1 and 20 mg/d, and in six studies children consumed doses of between 21 and 45 mg/d (20,21,33,45,49,67).

In one study children received a dose of 50 mg weekly (42) and two studies gave a 70 mg bolus either weekly (66) or twice weekly (18).

Only 10 (13,17,19,34,37,40,47,48,60,75) studies included in the meta-analyses included dietary zinc intake data. Estimated dietary zinc intake from the studies included in the meta-analyses can be found in **Table 2 of the supplementary file 2**.

A total of 39 studies from 41 articles (8,12,13,17–19,26,28–40,43,47,48,51,53–55,58–60,62–65,67,70–75) were included in meta-analyses. The outcomes that were examined through meta-analyses, were hemoglobin, anemia, serum ferritin, serum copper, iron deficiency, serum transferrin receptor (sTfR), hematocrit, c-reactive protein (CRP), Erythrocyte SOD (eSOD), zinc Protoporphyrin (ZPP), serum total cholesterol, lactulose:mannitol molar ratio, and serum iron concentration.

A total of 32 studies (8,13,18,26,27,29–34,36,41–46,49,50,55,56,58,59,61,63,67,69,72,74–76) included physical and clinical outcomes (i.e., vomiting, regurgitation, nausea, constipation, abdominal pain, drowsiness, mouth irritation, taste aversion, diarrhea, and dysentery). These studies are summarized narratively.

The GRADE, ROB and JBI quality assessment of the studies can be found in

Supplementary file 3. Less than 20% of studies were at high risk of bias using Cochrane

RoB 2 criteria, with risk of bias in the randomization process being the main contributor.

After consideration of risk of bias, inconsistency, indirectness, imprecision, and publication bias, GRADE certainty of evidence assessments for meta-analyses ranged from very low to moderate quality. Certainty of the evidence was primarily downgraded for risk of bias, indirectness (where study populations included some older children and/or had underlying morbidities), and imprecision.

Meta-analyses of the biochemical outcomes

Outcome measures from all studies were mapped and, where reported in 2 or more studies, were considered for meta-analysis. A summary of the biochemical outcome measures considered for meta-analyses is presented in **Table 2**. Where possible, forest plots have been generated for the following: age category [0-90 days, 91-180 days, 6-<12 months, ≥12 months]; dose of zinc given [<5mg/d, 5-10 mg/d, 10.1-20mg/d, >20 mg/d, bolus]; duration of intervention [0-3 months, > 3 months]; chemical formula of zinc [gluconate, sulphate, acetate, not stated, other] ; zinc vs placebo; and high vs low dose of zinc.

Hemoglobin

Thirty-two studies (8,12,13,18,19,26,28,29,31,33–40,43,47,48,51,53,54,58,59,62,64,65,70–73) assessed the effect of zinc on hemoglobin, all of which were included in the meta-analyses. The pooled analyses of the effect of zinc supplementation on hemoglobin concentration (g/L) by age and dose, showed that overall, there was no evidence for an impact of zinc on hemoglobin levels in infants aged between 0 and 90 days when doses of 4-10 mg/d (mg/d) were provided (Figure 2). In children aged 91-180 days, doses of 5-10 mg/d were associated with a significant reduction in hemoglobin concentration (mean difference

(MD) [95% confidence intervals (CI)] = - 2.39 g/L [-3.94, -0.84], $I^2=28\%$) (**Figure 3**).

Pooled analyses of studies with children aged 6-12 months (**Figure 4**) and > 12 months (**Figure 5**) showed that at the doses assessed, there were no significant effects on hemoglobin concentration.

No significant effect of zinc on hemoglobin levels were found in studies grouped by study duration, chemical formula, or comparator group, as summarized in **Table 3**. The quality of evidence for hemoglobin assessed using GRADE ranged from very low to moderate (**Supplementary file 3**).

Anemia and severe anemia

The effect of zinc supplementation on the odds ratio (OR) for anemia (defined as < 10.0 – 11.0 g/dL) was explored in all age categories. Only one study, Carter 2018 (12) included children aged 0-90 days. Doses of 5-10 mg/d of zinc were provided with no significant effect on the odds ratio for anemia OR [95%CI] = 1.20 [0.89, 1.60], $I^2=NA$). Three studies (29,39,71) (6 data sets) included children aged 91-180 days. All studies administered doses of 5-10 mg/d with and without additional iron, compared with iron alone or placebo, respectively (**Figure 6**). In children aged 6-12 months, seven studies (34,36,38,43,47,53,73) (14 comparisons) examined doses of zinc with and without combinations of iron, multiple micronutrients (MMN) and vitamin C (**Figure 7**). In children aged >12 months, six studies (19,37,48,54,55,70) (9 comparisons) investigated zinc supplementation with and without combinations of vitamin A, iron and MMN. (**Figure 8**). In all age groups, there was no significant effect of zinc supplementation on the OR for anemia.

Pooled analyses of the OR for anemia by duration of intervention, chemical formula of zinc supplement and comparator (placebo or high vs low zinc dose) are summarized in **Table 4**.

Zinc supplementation had no effect on the OR for anemia when data were grouped by

chemical formula and comparator. When grouped by study duration, two studies (48,73) had interventions that lasted for 0-3 months, and fifteen studies (12,19,29,34,36–39,43,47,53–55,70,71) (26 comparisons) had interventions that lasted longer than 3 months. In both duration categories children received doses of 3-10 mg/d. For studies with interventions of a shorter duration, the OR for anemia increased significantly with zinc supplementation (**Table 4**). For studies of longer duration, the overall OR for developing anemia was not significantly changed by zinc supplementation.

The impact of zinc supplementation on the risk for severe anemia was examined by three studies (12,63,64) and defined as hemoglobin level less than 70 g/L in two studies (63,64) and <85 g/L in one study (12). Combining data from these three studies did not reveal a significant impact of zinc supplementation at doses of 5-10 mg/d on the odds ratio for severe anemia OR [95% CI]: 1.00 [0.77, 1.28], $I^2 = 0\%$).

The quality of evidence for anemia assessed using GRADE ranged from very low to moderate (**Supplementary file 3**).

Serum ferritin

The effect of zinc supplementation on serum ferritin ($\mu\text{g/L}$) in children was assessed by age category and dose. Meta-analysis showed that in children aged 91-180 days, a dose of 10 mg/d resulted in a significantly lower serum ferritin concentration than in controls. However, no significant effect was observed in children aged 0-90 days, 6-12 months or >12 months at any of the doses assessed (**Figure 9 - 12**).

When assessed by dose and duration of intervention (across all ages), no significant difference was found in serum ferritin concentration compared with controls neither in interventions lasting less than three months nor in those lasting more than three months

(**Table 5**). No significant effect associated with the zinc chemical formula could be detected with the data available (**Table 5**).

The quality of evidence for serum ferritin using GRADE ranged from very low to moderate (**Supplementary file 3**).

Serum/plasma copper concentration

Zinc supplementation had no significant effect on serum/plasma copper concentration ($\mu\text{g/dL}$) at any dose in children aged 0-3 months (data from one study (8) $p=0.056$) or those aged 3-6 months (**Figure 13**). However, in age groups, 6-12 months and >12 months (**Figure 14 and 15**), doses of 3-20 mg/d have a significant, negative effect on serum/plasma copper concentration.

The effect of zinc supplementation on serum copper concentrations across all age groups was analyzed by duration of intervention, chemical formula of zinc supplement, and comparator group (**Table 6**). From the two studies (32,67) with interventions shorter than three months, only one (32) reported a highly significant impact of a dose of 18 mg/d, given with MMN, compared with a placebo plus MMN in children >12 months of age. For interventions longer than three months, data from one study (30), showed that a dose of 10-20 mg/d was associated with a significant reduction in serum/plasma copper concentration. This association was not shown for interventions with zinc doses up to and including 0-10 mg/d zinc or a bolus of 20-21 mg/wk.

Two studies used zinc gluconate, one at a dose of 10 mg/d of elemental zinc (62) and the other at 10-20 mg/d of elemental zinc depending on participant age (30). The overall effect was a significant reduction in serum/plasma copper concentration, mainly driven by the large effect at the higher dose. The overall effect of zinc sulphate, acetate, zinc-fortified breakfast (17) and non-stated forms of zinc were not significant. However, studies using zinc sulphate

at a elemental zinc dose of 3 mg/d (34) and 18 mg/d zinc with MMN (32) had a deleterious impact on serum/plasma copper concentrations. Combining studies where the comparator arm was a placebo, there was an overall significant effect of zinc in serum/plasma copper concentration **Table 5**.

The quality of evidence for copper using GRADE ranged from very low to moderate (**Supplementary file 3**).

Iron deficiency

Analysis of the effect of zinc supplementation on the OR for iron-deficiency (serum ferritin concentration <12 µg/L) by age showed a significantly increased OR in infants younger than three months (**Figure 16**). However, this was derived from a single study (73), providing a dose of 10 mg/d zinc, with and without MMN. In older children, pooled analysis showed no evidence of a significant effect of zinc supplementation on the OR for iron deficiency at the doses, intervention duration or chemical formula used in the studies.

The quality of evidence for iron deficiency using GRADE ranged from very low to moderate (**Supplementary file 3**).

Iron deficiency anemia

No significant association was observed between zinc intake and the odds of iron deficiency anemia (defined as having both anemia and ID) in any of the assessed age categories (**Figure 17**), zinc dose, duration of dose or zinc chemical formula (**Table 8**). No studies were conducted in children under three months or in those older than 12 months.

The quality of evidence for iron deficiency using GRADE ranged from very low to low (**Supplementary file 3**).

Serum transferrin receptor (sTfR)

Five studies examined the impact of zinc (5-20 mg/d) on sTfR (mg/L). Of these, one study (12) analyzed the effect of zinc on sTfR in children 0-3 months (mg/L); results showed no significant effect of a dose of 5-10 mg/d on sTfR (**Figure 18**). Four studies (28,36,47,74) examined the impact of 5-20 mg/d on sTfR (mg/L) in children 6-12 months. Overall, there was a significant impact of zinc on sTfR, indicating worsening iron status with zinc supplementation (**Figure 18**). No data was available for children aged 91-180 days or for those aged over 12 months.

A statistically significant negative impact on sTfR was observed when zinc sulphate was administered. No significant effects were observed when data were combined by other chemical formula, duration of intervention or comparator (**Table 9**).

The quality of evidence for sTfR using GRADE ranged from very low to moderate (**Supplementary file 3**).

Hematocrit

There was no overall effect of zinc supplementation on hematocrit in children aged 0-3 months, 6-12 months or >12 months (**Figure 19**). Zinc doses ranged from 4-12.3 mg/d, with additional supplements including iron, folic acid, and MMN. The duration of the intervention was greater than 3 months in all studies, except Moradveisi et al. (51). When examined by chemical formula, one study reported that zinc gluconate had a significant positive effect in hematocrit MD [95% CI] = 0.02% [0.00, 0.03], $p=0.04$ (62). No other significant effects were observed. (**Table 10**).

The quality of evidence for hematocrit using GRADE ranged from very low to moderate (**Supplementary file 3**).

C-reactive protein (CRP)

Data assessing the effect of zinc intake on CRP were limited, and there are no data in children under the age of six months, but data suggests there is no association between zinc supplementation and the likelihood of raised CRP in children aged over six months (**Figure 20**). The duration of the intervention for all studies was >3 months. None of the studies stated the chemical formula of the zinc administered. The combined data from all studies showed no significant effect of duration of treatment or chemical formula on the likelihood of raised CRP (**Table 11**).

The quality of evidence for CRP using GRADE was low (**Supplementary file 3**).

Erythrocyte SOD (eSOD)

Two studies reported the effect of zinc supplementation on eSOD. Wuehler et al. (72) provided a dose of 10 mg/d of elemental zinc (zinc sulphate) and Bates et al. (18) administered two bolus doses of 70 mg of elemental zinc per week (zinc gluconate). Both studies compared zinc against a placebo in children aged over 12 months. Combining the data from the two studies showed no overall significant effect on eSOD (**Figure 21**).

The quality of evidence for eSOD using GRADE was low (**Supplementary file 3**).

Zinc Protoporphyrin (ZPP)

Two studies (53,74) measured ZPP following doses of 5-10 mg/d for a period > 3 months.

The pooled analysis revealed that zinc supplementation had no significant effect on ZPP (**Figure 22**).

The quality of evidence for ZPP using GRADE was very low (**Supplementary file 3**).

Serum total cholesterol

Three studies assessed the effect of zinc on serum total cholesterol (mg/dL). One study (8), examined serum total cholesterol in children aged 0-3 months and two studies (17,72) were conducted with children aged over 12 months. There was no significant effect on zinc in any age group (**Figure 23**). All three studies had an intervention period of >3months with doses ranging from 3.75 to 10 mg/d of elemental zinc, either in the form of zinc sulphate (8,72), or in a fortified breakfast cereal (17). Grouping the studies by dose, mode of delivery, duration and zinc vs placebo did not reveal any significant impact of zinc supplementation on total blood cholesterol concentration (**Table 12**).

The quality of evidence for serum total cholesterol using GRADE ranged from very low to low (**Supplementary file 3**).

Lactulose:mannitol molar ratio

Two studies (18,60) reported the effect of zinc supplementation on lactulose:mannitol molar ratio. Both studies were conducted with children older than 12 months. Overall, there was a significant reduction in the ratio following zinc supplementation, indicating reduced (improved) gut permeability (**Figure 24**). Ryan et al. (60) provided a dose of 20 mg/d of elemental zinc in the form of zinc acetate for a period <3months. This dose regimen yielded a significant reduction in the ratio compared with a placebo. Bates et al. (18) provided a dose of 70 mg of elemental zinc, twice a week, in the form of zinc sulphate for a period > 3 months. There was a fall in the ratio compared with placebo, but it failed to reach statistical significance (**Table 13**).

The quality of evidence for lactulose:mannitol molar ratio using GRADE ranged from very low to low (**Supplementary file 3**).

Serum iron concentration

Two studies assessed the effect of zinc on serum iron concentration ($\mu\text{g/dL}$). Both studies were conducted with children older than two years (51,65). Pooling data from both studies revealed no significant effect on serum iron concentrations (**Figure 25**). Moradveisi et al. (51) provided a dose of 12.3 mg/d of elemental zinc as zinc sulphate with iron (60 mg/d) or iron alone (60 mg/d) for a period <3 months with no significant effect. Silva et al. (65) provided a dose of 10 mg/d of elemental zinc as zinc sulphate or a placebo for >3 months. There was a significant increase in serum iron following zinc supplementation (**Table 14**). The quality of evidence for serum iron using GRADE was very low (**Supplementary file 3**).

Narrative description of physical and clinical outcomes

Vomiting, regurgitation and nausea

Thirteen studies (8,27,30,36,41,44–46,49,50,67,69,76) reported on the effect of zinc supplementation on the occurrence of vomiting (8,27,30,36,41,44–47,49,50,67,69).

Overall, four (30,46,67,69) of the 13 studies found a higher incidence of vomiting following zinc supplementation, with single daily zinc doses ranging from 10 to 20 mg for infants under 12 months of age and 20 to 30 mg/d for children aged ≥ 12 months. Three studies were of short duration (10 to 14 days) in children with acute diarrhea (46,67) or pneumonia (69), and one study (30) was of four months duration for the prevention of diarrhea. In Chang et al. (36), zinc provided at the same time as iron resulted in a significant increase in the frequency of vomiting compared with placebo or other intervention groups where zinc alone or zinc with iron provided separately

Five studies (8,33,46,67,69) reported on post-treatment regurgitation. Three studies found an increased frequency of regurgitation in children with acute diarrhea (46,67) or pneumonia (69), who received single daily zinc doses ranging from 10 to 20 mg (infants under 12 months of age) or 20 to 30 mg/d (children aged ≥ 12 months) for 10-14 days. One study (33) administered weekly zinc doses of 21 mg to children aged 2 to 11 months for 12 months for the prevention of diarrhea and pneumonia cited taste aversion sometimes leading to regurgitation as a potential reason for the higher number of withdrawals amongst the treatment group (n=103 vs n=44 in the placebo group).

Two studies (44,45) reported on the frequency of nausea without specifying its relation to timing of treatment. Neither study found an increase in reports of nausea with zinc supplementation.

Constipation and abdominal pain

Four studies reported on the effect of zinc on constipation (44,45,49,50), none of found a significant difference between treatment groups. (50)

Three trials (41,44,45) reported on the occurrence of abdominal pain without specifying its relation to timing of treatment. No significant differences between treatment groups were found.

Drowsiness

Two studies (44,45) reported on the effect of zinc on drowsiness; neither study found a significant increase in reports of drowsiness with zinc supplementation.

Mouth irritation and taste aversion

Two studies (44,45) reported on the frequency of mouth irritation without specifying its relation to timing of treatment. Both studies used a syrup formulation with 15 mg/d of

elemental zinc as zinc sulphate in 5 mL of syrup; neither study found an increase in mouth irritation with zinc supplementation. Three studies (33,44,45) reported on taste aversion to zinc syrup, provided as 21 mg/d elemental zinc acetate in 10mL syrup (33) or 15 mg/d elemental zinc as zinc sulphate in 5 mL syrup (44,45). Only Brooks et al. (33), reported taste aversion, sometimes leading to regurgitation and was highlighted as a potential reason for the higher number of withdrawals amongst the treatment group (n=103 vs n=44 in the placebo group) (44,45).

Diarrhea and dysentery

Twenty-seven studies (8,13,18,26,27,29–34,36,42–45,49,50,55,56,58,59,61,63,67,72,75) reported on the effect of zinc on diarrhea, with the majority (n=23) investigating zinc supplementation for the prevention or treatment of diarrhea. Four studies (8,44,45,49) suggested that zinc supplementation may have a potential adverse effect on diarrheal incidence (8,44,77). None of the included studies reported a significant increase in or worsening of diarrhea with zinc supplementation.

Three studies (36,42,55) reported on the effect of zinc on dysentery or bloody/mucoid diarrhea in children. None of the studies reported a worsening of the condition as a result of zinc supplementation given alone or in combination with iron. Two of these studies reported an improvement in the dysentery, one when zinc was provided alone (42,55) and one when zinc was provided at the same time as iron (36).

Case studies

Two case studies were identified. Botash et al. (20) reported data from a 6-month-old infant given a dose of 16-24 mg/d zinc prophylactically. Adverse effects were noted for hematological indices, including serum copper, ceruloplasmin, serum iron. Sugiura et al. (21)

reported on an 11-month-old infant with atopic dermatitis who consumed 45 mg/d zinc, and recorded adverse effects on serum copper, ceruloplasmin and hemoglobin.

Discussion

The setting of ULs for zinc has previously been considered by international panels, including those convened by FAO-WHO (2004)(1), IOM (78), IZiNCG (7) and the European Food and Safety Authority (3). An early step in this process is to collate data from published literature that enable the relationship between zinc intake and adverse effects on key outcomes to be described. To date, however, this has been hindered by a lack of data in the 0-3 year age range. Our search identified 62 studies that assessed possible adverse effects of zinc intake in children aged 0-3 years with zinc doses ranging from 3 to 70 mg/d. In most studies doses were below 20 mg/d. Data from 39 studies allowed meta-analyses of outcome measures of interest, as identified by the FAO-WHO expert group. Meta-analyses revealed that zinc supplementation had a significant adverse effect on serum ferritin, plasma/serum copper concentration, sTfR, hemoglobin, hematocrit, and the odds of anemia in at least one of the subgroups of pooled data. A significant reduction of lactulose:mannitol ratio was found, indicating improved gut permeability. No significant effect of zinc supplementation on CRP, eSOD, ZPP, blood cholesterol, or iron deficiency anemia were observed in any of the pooled datasets.

Our analyses revealed a significant reduction in serum copper concentration following zinc supplementation in children aged >6-12 months (**Figure 14**) and >12 months (**Figure 15**). Mean reductions were 3.17 and 5.25 µg/dL respectively. Despite this decrease, the mean serum copper concentration reported in each of the studies remained within the reference range post intervention (children <1 year: 71.16-168.11 µg/dL) (79); 0.5-2 years: 72-178 µg/dl (80) and 3-4 years 80-160 (80)), with the exception of one study where children were

recovering from diarrhea and had low baseline serum copper levels (32). This example raises the question about the point at which a change in biochemical outcome measure becomes clinically important, such that the zinc dose that resulted in the change would be considered to pose a risk to health. This can be further explored using dose response modelling to determine the zinc intake required to result in a clinically significant change in either serum copper concentration or serum ferritin concentration, including the contribution from background dietary zinc intake, in children of various age categories (81). Identifying the threshold value that corresponds to this clinically significant change is also a crucial part of this risk assessment process.

A competitive interaction between zinc and iron during intestinal absorption has been long debated (82), and it has been proposed that high zinc intakes could induce a secondary iron deficiency. In addition to serum ferritin, outcome measures relating to iron status that were included in our meta-analyses include hemoglobin, hematocrit, iron deficiency (measured by: plasma ferritin concentration $<12 \mu\text{g/L}$) iron deficiency anemia (measured by hemoglobin $<11 \text{ g/dL}$ and plasma ferritin $<12 \mu\text{g/L}$), serum iron concentration and sTfR. Meta-analysis of pooled data revealed that hemoglobin concentration was significantly reduced in children aged 91-180 days following zinc doses of 5-10 mg/d (**Figure 6**), but there was no significant effect on mean values from data pooled by age in the younger or older age categories. Hematocrit and serum iron concentration data were sparse, but analysis of pooled data provided no evidence for a significant effect of zinc supplementation on these outcome measures. Similarly, analysis of the pooled data from studies reporting the risk of iron deficiency anemia and anemia did not reveal any significant effect of zinc supplementation on the OR in any of the age categories for which there were data (**Figures 6-8, Table 7**).

However, combining data from studies with a short duration (< 3 months) did reveal a significant increase in the OR for anemia indicating a possible short-term effect (**Table 4**).

Levels of sTfR are high when iron deficiency is present, and in situations of increased erythropoietic activity (83). Most of the studies included in the meta-analysis were conducted in children aged 6-12 months. Analysis of the pooled data indicated a highly significant, detrimental increase of sTfR levels. In some studies, children in the intervention but also in the comparison groups (36,47,74) had levels of sTfR above the reference values for healthy children proposed by some studies (83–85). However, there is a lack of standardization on the methods used to determine sTfR, which limits the comparability of the results and our understanding of the severity of the effect of zinc on sTfR levels (83).

The urinary lactulose:mannitol ratio is a biomarker for environmental enteropathy, and its reduction indicates a fall in the gut permeability which is a desirable outcome from zinc supplementation. Meta-analysis of the data from the two studies that reported this outcome showed a statistically significant reduction of the lactulose:mannitol ratio following zinc supplementation in children over 12 months old. This concurs with previous systematic reviews that have investigated the effectiveness of zinc supplementation as a treatment for diarrhea in children (86).

Doses of zinc ranging from 10 to 20 mg/day in infants under 12 months of age and 20 to 30 mg/day for children aged ≥ 12 months increase the risk of vomiting (30,46,67,69) and regurgitation (46,67,69) in some studies. From the studies reporting on taste aversion, only one study (33), reported it as leading to regurgitation and authors highlighted it as a potential reason of withdrawals among the children in the zinc arm. The studies reporting on for nausea, constipation, abdominal pain, mouth irritation or dysentery did not find an increase incidence of these adverse effects as a result of the zinc doses provided.

Overall, the certainty of the evidence, as assessed using GRADE, was very low to moderate. Factors influencing the downgrading of the evidence included the presence of underlying

morbidities and the inclusion of older children in some studies, imprecision in effect estimates due to low numbers and/or heterogeneity, and risk of bias due to randomization processes. Given these limitations in the certainty of the evidence, it is possible that data from further trials may alter the effect estimates summarized here.

Strengths and Limitations

Studies that have collected data on the potential adverse effects of zinc intake in children aged 0-3 years are scarce. As a consequence, it was not possible to conduct meta-analyses by age category, dose, dose duration, and chemical formula of zinc for all the outcomes explored. Additionally, most studies included data from children with relatively low exposures to zinc where adverse effects at such ranges may not be expected. Therefore, it was not possible to identify dose ranges in which zinc may be detrimental for most individuals in the target age group. Nonetheless, data from this review may be used by expert groups to conduct dose response modelling to establish the tolerable upper intake levels of zinc in children aged 0-3 years.

Conclusion

Whilst zinc supplementation at doses of 3 to 20 mg/d had an adverse effect on levels of serum/plasma copper, ferritin, hemoglobin and sTfR in children aged 0-3 years, the change observed may not have a detrimental effect on healthy populations. However, recommended maximum zinc doses may need to be adjusted for children at risk or recovering from iron or copper deficiency. Data from this review may be used to undertake dose response modelling to estimate tolerable upper intake level of zinc in children aged 0-3 years.

Acknowledgments

The authors are grateful to the following researchers for responding to requests for dietary zinc intake data: M Abdollahi, E Becquey, L Diop, M Dijkhuizen, U Fahmida, S Hess, P Kolsteren, T Lind, J Rosado, H Sommerfelt, T Strand, H Verhoef, F Wieringa, and P Winichagoon.

We thank the members of the FAO-WHO expert group for their assistance during the identification, selection, and synthesis of papers for this review. This study has been made possible through funding from FAO and WHO. AC is part of the National Institute for Health Research (NIHR) Applied Research Collaboration North West Coast (ARCNCW). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or Department of Health and Social Care.

Statement of Authors' contributions to manuscript

NML, JM and MX conceptualized the review. CH and MCR searched the databases, AC conducted the meta-analyses, MCR, SM, VHM and NML assessed the records, SM extracted the data, collated dietary data, conducted GRADE and risk of bias assessments, MX and SM contacted authors for dietary data, MCR, NML, SM and VHM contributed to drafting of the manuscript. All authors contributed to the study design, provided the methodology for the study, and edited and revised the manuscript.

Notes

Abbreviations used: CRP, c-reactive protein; CI, confidence intervals; eSOD, Erythrocyte SOD; GRADE, Grading of Recommendations Assessment, Development, and Evaluation; JBI, Joanna Briggs Institute; ID, Iron deficiency; IDA, Iron deficiency anemia; IOM, Institute of Medicine; IZiNCG, International Zinc Nutrition Consultative Group; FAO, Food and

Downloaded from <https://academic.oup.com/advances/advance-article/doi/10.1093/advances/nmac088/6687800> by guest on 07 September 2022

Data collection forms: data extracted from included studies; data used for all analyses is available upon request to the corresponding author.

1. World Health Organization/Food and Agriculture Organization of the United Nations. Vitamin and mineral requirements in human nutrition [Internet]. 2nd ed. World Health Organization, editor. Geneva, Switzerland; 2004. 341 p. Available from: <http://apps.who.int/iris/bitstream/handle/10665/42716/9241546123.pdf;jsessionid=A16E0CB2D96C7034FF573A649CC46D7B?sequence=1>
2. FAO/WHO (Food and agricultural Organisation of the UN/World Health Organisation) Expert Consultation. Application of risk analysis to food standards issues. Recommendations to the Codex Alimentarius Commission. (Alinorm 95/9, Appendix 5). 1995.
3. European Food Safety Authority (EFSA). Tolerable upper intake level on vitamins and minerals. [Internet]. 2006. Available from: http://www.efsa.eu.int/science/nda/nda_opinions/catindex_en.htm
4. King JC, Shames DM, Woodhouse LR. Zinc homeostasis in humans. J Nutr.

2000;130(5 SUPPL.).

5. Fosmire GJ. Zinc toxicity. *Am J Clin Nutr* [Internet]. 1990 Feb 1;51(2):225–7.
Available from: <https://academic.oup.com/ajcn/article/51/2/225/4695142>
6. Institute of Medicine (US) Panel on Micronutrients. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc [Internet]. Washington, D.C.: National Academies Press; 2001. Available from: <http://www.nap.edu/catalog/10026>
7. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lönnerdal B, et al. Assessment of the risk of zinc deficiency in populations and options for its control. *Food Nutr Bull* [Internet]. 2004 Mar;25(1 Suppl 2):S94-204. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75182010000200014&lng=en&nrm=iso&tlng=en
8. Walravens PA, Hambidge KM. Growth of infants fed a zinc supplemented formula. *Am J Clin Nutr*. 1976;29(10):1114–21.
9. World Health Organization/Food and Agriculture Organization of the United Nations. FAO/WHO nutrient requirements for children aged 0–36 months [Internet]. 2020. Available from: <https://www.who.int/groups/fao-who-nutrient-requirements-for-children-aged-0-36-months>
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* [Internet]. 2021 Mar 29;n71. Available from: <https://www.bmj.com/lookup/doi/10.1136/bmj.n71>
11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile

app for systematic reviews. Syst Rev [Internet]. 2016 Dec 5;5(1):210. Available from: [http://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0384-](http://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0384-4)

4

12. Carter RC, Kupka R, Manji K, McDonald CM, Aboud S, Erhardt JG, et al. Zinc and multivitamin supplementation have contrasting effects on infant iron status: A randomized, double-blind, placebo-controlled clinical trial. Eur J Clin Nutr [Internet]. 2018 Jan 6;72(1):130–5. Available from: <http://www.nature.com/articles/ejcn2017138>
13. Radhakrishna K V, Hemalatha R, Geddam JJB, Kumar PA, Balakrishna N, Shatrugna V. Effectiveness of zinc supplementation to full term normal infants: a community based double blind, randomized, controlled, clinical trial. PLoS One [Internet]. 2013;8(5):e61486. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23737940>
14. Rios-Leyvraz M, Yao Q. Breast Milk Intake and Content in Calcium, Vitamin D and Zinc. Meeting of FAO-WHO expert group on nutrient requirements. 2021.
15. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV, editor. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022) [Internet]. Cochrane; 2022. Available from: www.training.cochrane.org/handbook
16. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 Aug 28;14898. Available from: <https://www.bmj.com/lookup/doi/10.1136/bmj.14898>
17. Hambidge KM, Chavez MN, Brown RM, Walravens PA. Zinc nutritional status of young middle-income children and effects of consuming zinc-fortified breakfast cereals. Am J Clin Nutr. 1979;32(12):2532–9.

18. Bates CJ, Bates PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, et al. A trial of zinc supplementation in young rural Gambian children. *Br J Nutr*. 1993;69(1):243–55.
19. Mendoza NJ, Del Y, Peña CB, Frank Papalé-Centofanti J, Torres-Villanueva M, Castro M. Anthropometric and biochemical nutritional status, parasitic infestation, social stratification. The effects of zinc supplementation in children of Venezuelan public kindergartens. *Rev Esp Nutr Comunitaria*. 2016;22(2).
20. Botash AS, Nasca J, Dubowy R, Weinberger HL, Oliphant M. Zinc-Induced Copper Deficiency in an Infant. *Arch Pediatr Adolesc Med* [Internet]. 1992 Jun 1;146(6):709. Available from:
<https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1595625>
21. Sugiura T, Goto K, Ito K, Ueta A, Fujimoto S, Togari H. Chronic zinc toxicity in an infant who received zinc therapy for atopic dermatitis. *Acta Paediatr* [Internet]. 2005 Sep 5;94(9):1333–5. Available from:
<https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med6&AN=16203677>
22. Joanna Briggs Institute. Critical appraisal tools [Internet]. 2020 [cited 2021 Mar 5]. Available from: <https://jbi.global/critical-appraisal-tools>
23. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* [Internet]. 2011 Apr;64(4):380–2. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/S089543561000329X>
24. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al.

- GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. *J Clin Epidemiol* [Internet]. 2019 Jul;111:105–14. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0895435617310314>
25. Ryan R, Hill S. How to GRADE the quality of the evidence [Internet]. Cochrane Consumers and Communication Group; 2016. Available from: <http://cccr.org.cochrane.org/author-resources>
26. Alarcon K, Kolsteren PW, Prada AM, Chian AM, Velarde RE, Pecho IL, et al. Effects of separate delivery of zinc or zinc and vitamin A on hemoglobin response, growth, and diarrhea in young Peruvian children receiving iron therapy for anemia. *Am J Clin Nutr*. 2004;80(5):1276–82.
27. Awasthi S. Zinc Supplementation in Acute Diarrhea is Acceptable, Does Not Interfere with Oral Rehydration, and Reduces the Use of Other Medications. *J Pediatr Gastroenterol Nutr* [Internet]. 2006 Mar;42(3):300–5. Available from: <http://journals.lww.com/jpgn>
28. Baqui AH, Fischer Walker CL, Zaman K, El Arifeen S, Chowdhury HR, Wahed MA, et al. Weekly iron supplementation does not block increases in serum zinc due to weekly zinc supplementation in Bangladeshi infants. *J Nutr*. 2005;135(9):2187–91.
29. Berger J, Ninh NX, Khan NC, Nhien N V., Lien DK, Trung NQ, et al. Efficacy of combined iron and zinc supplementation on micronutrient status and growth in Vietnamese infants. *Eur J Clin Nutr*. 2006;60(4):443–54.
30. Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, et al. Substantial Reduction in Severe Diarrheal Morbidity by Daily Zinc Supplementation in Young North Indian Children. *Pediatrics* [Internet]. 2002 Jun 1;109(6):e86–e86. Available

32. Bhutta ZA, Nizami SQ, Ismail Z. Diarrhoea in Pakistan. *Pediatrics*. 1999;103(4):1-9.
33. Brooks WA, Santosham M, Naheed A, Goswami D, Wahed MA, Diener-West M, et al. Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. *Lancet* [Internet]. 2005 Sep;366(9490):999-1004. Available from: <https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed9&AN=41327324>
34. Brown KH, De Romaña DL, Arsenault JE, Peerson JM, Penny ME. Comparison of the effects of zinc delivered in a fortified food or a liquid supplement on the growth, morbidity, and plasma zinc concentrations of young Peruvian children. *Am J Clin Nutr*. 2007;85(2):538-47.
35. Caulfield LE, Zavaleta N, Chen P, Colombo J, Kannass K. Mineral status of non-anemic Peruvian infants taking an iron and copper syrup with or without zinc from 6 to 18 months of age: A randomized controlled trial. *Nutrition* [Internet]. 2013 Nov;29(11-12):1336-41. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0899900713002815>
36. Chang S, El Arifeen S, Bari S, Wahed MA, Rahman KM, Rahman MT, et al. Supplementing iron and zinc: Double blind, randomized evaluation of separate or

combined delivery. *Eur J Clin Nutr* [Internet]. 2010 Feb 11;64(2):153–60. Available from: <http://www.nature.com/articles/ejcn2009127>

37. Chen L, Liu YF, Gong M, Jiang W, Fan Z, Qu P, et al. Effects of vitamin a, vitamin a plus zinc, and multiple micronutrients on anemia in preschool children in Chongqing, China. *Asia Pac J Clin Nutr*. 2012;21(1):3–11.
38. Chhagan MK, Van Den Broeck J, Luabeya KKA, Mpontshane N, Tomkins A, Bennish ML. Effect on longitudinal growth and anemia of zinc or multiple micronutrients added to vitamin A: A randomized controlled trial in children aged 6-24 months. *BMC Public Health*. 2010;10:1–11.
39. Dijkhuizen MA, Wieringa FT, West CE, Martuti S, Muhilal. Effects of iron and zinc supplementation in Indonesian infants on micronutrient status and growth. *J Nutr*. 2001;131(11):2860–5.
40. Fahmida U, Rumawas JSP, Utomo B, Patmonodewo S, Schultink W. Linear Growth of Stunted Infants With Low Haemoglobin. *Asia Pac J Clin Nutr*. 2007;16(October 2006):301–9.
41. Fallah R, Sabbaghzadegan S, Karbasi SA, Binesh F. Efficacy of zinc sulfate supplement on febrile seizure recurrence prevention in children with normal serum zinc level: A randomised clinical trial. *Nutrition*. 2015 Nov 1;31(11–12):1358–61.
42. Gupta DN, Mondal SK, Ghosh S, Rajendran K, Sur D, Manna B. Impact of zinc supplementation on diarrhoeal morbidity in rural children of West Bengal, India. *Acta Paediatr Int J Paediatr*. 2003 May 1;92(5):531–6.
43. Hess SY, Abbeddou S, Jimenez EY, Somé JW, Vosti SA, Ouédraogo ZP, et al. Small-Quantity Lipid-Based Nutrient Supplements, Regardless of Their Zinc Content,

Increase Growth and Reduce the Prevalence of Stunting and Wasting in Young Burkinabe Children: A Cluster-Randomized Trial. *PLoS One*. 2015;10(3):e0122242.

44. Kurugöl Z, Akilli M, Bayram N, Koturoglu G. The prophylactic and therapeutic effectiveness of zinc sulphate on common cold in children. *Acta Paediatr* [Internet]. 2006 Oct 1;95(10):1175–81. Available from: <http://doi.wiley.com/10.1080/08035250600603024>
45. Kurugöl Z, Bayram N, Atik T. Effect of zinc sulfate on common cold in children: Randomized, double blind study. *Pediatr Int*. 2007;49(6):842–7.
46. Larson CP, Hoque ABMM, Larson CP, Khan AM, Saha UR. Initiation of zinc treatment for acute childhood diarrhoea and risk for vomiting or regurgitation: A randomized, double-blind, placebo-controlled trial. *J Heal Popul Nutr*. 2005;23(4):311–9.
47. Lind T, Lönnerdal B, Stenlund H, Ismail D, Seswandhana R, Ekström E-C, et al. A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc. *Am J Clin Nutr* [Internet]. 2003 Apr 1;77(4):883–90. Available from: <https://academic.oup.com/ajcn/article/77/4/883/4689762>
48. López De Romaña D, Salazar M, Hambidge KM, Penny ME, Peerson JM, Krebs NF, et al. Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. *Am J Clin Nutr*. 2005;81(3):637–47.
49. Malik A, Taneja DK, Devasenapathy N, Rajeshwari K. Zinc supplementation for prevention of acute respiratory infections in infants: A randomized controlled trial. *Indian Pediatr*. 2014;51(10):780–4.

50. Martinez-Estevez NS, Alvarez-Guevara AN, Rodriguez-Martinez CE. Effects of zinc supplementation in the prevention of respiratory tract infections and diarrheal disease in Colombian children: A 12-month randomised controlled trial. *Allergol Immunopathol (Madr)* [Internet]. 2016 Jul 1;44(4):368–75. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0301054616300192>
51. Moradveisi B, Yazdanifard P, Naleini N, Sohrabi M. Comparison of iron alone and zinc plus iron supplementation effect on the clinical and laboratory features of children with iron deficiency anemia. *Int J Hematol Stem Cell Res*. 2019;13(4):220–8.
52. Muñoz EC, Rosado JL, López P, Furr HC, Allen LH. Iron and zinc supplementation improves indicators of vitamin A status of Mexican preschoolers. *Am J Clin Nutr* [Internet]. 2000 Mar 1;71(3):789–94. Available from: <https://academic.oup.com/ajcn/article/71/3/789/4729207>
53. Olney DK, Pollitt E, Kariger PK, Khalfan SS, Ali NS, Tielsch JM, et al. Combined iron and folic acid supplementation with or without zinc reduces time to walking unassisted among Zanzibari infants 5- to 11-mo old. *J Nutr*. 2006;136(9):2427–34.
54. Ouédraogo HZ, Dramaix-Wilmet M, Zeba AN, Hennart P, Donnen P. Effect of iron or multiple micronutrient supplements on the prevalence of anaemia among anaemic young children of a malaria-endemic area: A randomized double-blind trial. *Trop Med Int Heal*. 2008;13(10):1257–66.
55. Owusu-Agyei S, Newton S, Mahama E, Febir LG, Ali M, Adjei K, et al. Impact of vitamin A with zinc supplementation on malaria morbidity in Ghana. *Nutr J*. 2013;12(1):1–9.
56. Passariello A, Nocerino R, Terrin G, Cecere G, De Marco G, Micillo M, et al. Acceptability and efficacy of a gel hypotonic oral rehydration solution in children with

- acute gastroenteritis. *Eur J Gastroenterol Hepatol* [Internet]. 2015 May 14;27(5):523–6. Available from: <https://journals.lww.com/00042737-201505000-00007>
57. Rahman MM, Vermund SH, Wahed MA, Fuchs GJ, Baqui AH, Alvarez JO. Simultaneous zinc and vitamin A supplementation in Bangladeshi children: randomised double blind controlled trial. *BMJ* [Internet]. 2001 Aug 11;323(7308):314–8. Available from: <https://www.bmj.com/lookup/doi/10.1136/bmj.323.7308.314>
58. Richard SA, Zavaleta N, Caulfield LE, Black RE, Witzig RS, Shankar AH. Zinc and iron supplementation and malaria, diarrhea, and respiratory infections in children in the Peruvian Amazon. *Am J Trop Med Hyg*. 2006;75(1):126–32.
59. Rosado JL, López P, Muñoz E, Martinez H, Allen LH. Zinc supplementation reduced morbidity, but neither zinc nor iron supplementation affected growth or body composition of Mexican preschoolers. *Am J Clin Nutr*. 1997;65(1):13–9.
60. Ryan KN, Stephenson KB, Trehan I, Shulman RJ, Thakwalakwa C, Murray E, et al. Zinc or albendazole attenuates the progression of environmental enteropathy: A randomized controlled trial. *Clin Gastroenterol Hepatol* [Internet]. 2014;12(9):1–8. Available from: <http://dx.doi.org/10.1016/j.cgh.2014.01.024>
61. Sampaio DLB, de Mattos ÂP, Ribeiro TCM, Leite ME de Q, Cole CR, Costa-Ribeiro H. Zinc and other micronutrients supplementation through the use of sprinkles: impact on the occurrence of diarrhea and respiratory infections in institutionalized children. *J Pediatr (Rio J)* [Internet]. 2013 May;89(3):286–93. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00959582/full>
62. Sazawal S, Malik P, Jalla S, Krebs N, Bhan M, Black R. Zinc supplementation for four months does not affect plasma copper concentration in infants. *Acta Paediatr*

- [Internet]. 2004 May;93(5):599–602. Available from:
<https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15174779>
63. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in. *Lancet* [Internet]. 2006;367(9505):133–43. Available from:
http://www.sciencedirect.com/science?_ob=GatewayURL&_origin=ScienceSearch&_method=citationSearch&_piikey=S0140673606679622&_version=1&_returnURL=&md5=59b88b4fa0756164e14fc63cc3316c5c
64. Shankar AH, Genton B, Baisor M, Jaino P, Tamja S, Adiguma T, et al. The influence of zinc supplementation on morbidity due to *Plasmodium falciparum*: A randomized trial in preschool children in Papua New Guinea. *Am J Trop Med Hyg*. 2000;62(6):663–9.
65. Silva APR, Vitolo MR, Zara LF, Castro CFS. Effects of zinc supplementation on 1- to 5-year old children. *J Pediatr (Rio J)*. 2006;82(3):227–31.
66. Smith JC, Rao D, Makdani D, Hegar A, Douglass LW. Vitamin A and Zinc Supplementation of Preschool Children. *J Am Coll Nutr*. 1999;18(3):213–22.
67. Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, et al. Effectiveness and Efficacy of Zinc for the Treatment of Acute Diarrhea in Young Children. *Pediatrics* [Internet]. 2002 May 1;109(5):898–903. Available from:
<http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.109.5.898>
68. Surono IS, Martono PD, Kameo S, Suradji EW, Koyama H. Effect of probiotic *L. plantarum* IS-10506 and zinc supplementation on humoral immune response and zinc status of Indonesian pre-school children. *J Trace Elem Med Biol* [Internet].

- 2014;28(4):465–9. Available from: <http://dx.doi.org/10.1016/j.jtemb.2014.07.009>
69. Valentiner-Branth P, Shrestha PS, Chandyo RK, Mathisen M, Basnet S, Bhandari N, et al. A randomized controlled trial of the effect of zinc as adjuvant therapy in children 2–35 mo of age with severe or nonsevere pneumonia in Bhaktapur, Nepal. *Am J Clin Nutr*. 2010 Jun 1;91(6):1667–74.
70. Veenemans J, Milligan P, Prentice AM, Schouten LRA, Inja N, van der Heijden AC, et al. Effect of Supplementation with Zinc and Other Micronutrients on Malaria in Tanzanian Children: A Randomised Trial. von Seidlein L, editor. *PLoS Med* [Internet]. 2011 Nov 22;8(11):e1001125. Available from: <https://dx.plos.org/10.1371/journal.pmed.1001125>
71. Wasantwisut E, Winichagoon P, Chitchumroonchokchai C, Yamborisut U, Boonpradern A, Pongcharoen T, et al. Iron and Zinc Supplementation Improved Iron and Zinc Status, but Not Physical Growth, of Apparently Healthy, Breast-Fed Infants in Rural Communities of Northeast Thailand. *J Nutr* [Internet]. 2006 Sep 1;136(9):2405–11. Available from: <https://academic.oup.com/jn/article/136/9/2405/4664952>
72. Wuehler SE, Sempértegui F, Brown KH. Dose-response trial of prophylactic zinc supplements, with or without copper, in young Ecuadorian children at risk of zinc deficiency. *Am J Clin Nutr* [Internet]. 2008 Mar 1;87(3):723–33. Available from: <https://academic.oup.com/ajcn/article/87/3/723/4633435>
73. Zlotkin S, Arthur P, Schauer C, Antwi KY, Yeung G, Piekarz A. Home-Fortification with Iron and Zinc Sprinkles or Iron Sprinkles Alone Successfully Treats Anemia in Infants and Young Children. *J Nutr* [Internet]. 2003 Apr 1;133(4):1075–80. Available from: <https://academic.oup.com/jn/article/133/4/1075/4688097>

74. Abbeddou S, Yakes Jimenez E, Somé JW, Ouédraogo JB, Brown. KH, Hess SY. Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: A cl. BMC Pediatr [Internet]. 2017;17(1):1–17. Available from: <http://dx.doi.org/10.1186/s12887-016-0765-9>
75. Abdollahi M, Ajami M, Abdollahi Z, Kalantari N, Houshiarrad A, Fozouni F, et al. Zinc supplementation is an effective and feasible strategy to prevent growth retardation in 6 to 24 month children: A pragmatic double blind, randomized trial. Heliyon [Internet]. 2019 Nov;5(11):e02581. Available from: <https://doi.org/10.1016/j.heliyon.2019.e02581>
76. Lind T, Persson LÅ, Lönnerdal B, Stenlund H, Hernell O. Effects of weaning cereals with different phytate content on growth, development and morbidity: A randomized intervention trial in infants from 6 to 12 months of age. Acta Paediatr Int J Paediatr. 2004;93(12):1575–82.
77. Macknin ML, Piedmonte M, Calendine C, Janosky J, Wald E. Zinc Gluconate Lozenges for Treating the Common Cold in Children. JAMA [Internet]. 1998 Jun 24;279(24):1962. Available from: <https://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9643859>
78. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc [Internet]. Washington, D.C.: National Academies Press; 2001. Available from: <http://www.nap.edu/catalog/10026>

79. Ha F, Wu Y, Wang H, Wang T. The Reference Intervals of Whole Blood Copper, Zinc, Calcium, Magnesium, and Iron in Infants Under 1 Year Old. *Biol Trace Elem Res* [Internet]. 2022 Jan 24;200(1):1–12. Available from: <https://link.springer.com/10.1007/s12011-021-02620-6>
80. Lin CN, Wilson A, Church BB, Ehman S, Roberts WL, McMillin GA. Pediatric reference intervals for serum copper and zinc. *Clin Chim Acta* [Internet]. 2012;413(5–6):612–5. Available from: <http://dx.doi.org/10.1016/j.cca.2011.12.005>
81. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Model for the Development of Tolerable Upper Intake Levels. In: *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride* [Internet]. Washington (DC): National Academies Press (US); 1997. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK109818/>
82. Kondaiah P, Yaduvanshi PS, Sharp PA, Pullakhandam R. Iron and zinc homeostasis and interactions: Does enteric zinc excretion cross-talk with intestinal iron absorption? *Nutrients*. 2019;11(8).
83. Vázquez-López MA, López-Ruzafa E, Lendinez-Molinos F, Ortiz-Pérez M, Ruiz-Tudela L, Martín-González M. Reference values of serum transferrin receptor (sTfR) and sTfR/log ferritin index in healthy children. *Pediatr Hematol Oncol* [Internet]. 2016 Feb 17;33(2):109–20. Available from: <http://www.tandfonline.com/doi/full/10.3109/08880018.2015.1138007>
84. Larsson SM, Hillarp A, Karlsland Åkeson P, Hellström-Westas L, Domellöf M, Askelöf U, et al. Soluble Transferrin Receptor during infancy and reference intervals for the Roche Cobas platform. *Int J Lab Hematol*. 2021;43(3):378–86.
85. Ooi CL, Lepage N, Nieuwenhuys E, Sharma AP, Filler G. Pediatric reference intervals

for soluble transferrin receptor and transferrin receptor-ferritin index. *World J Pediatr.* 2009;5(2):122–6.

86. Patro B, GolickI D, Szajewska H. Meta-analysis: zinc supplementation for acute gastroenteritis in children. *Aliment Pharmacol Ther* [Internet]. 2008 Sep;28(6):713–23. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2008.03787.x>

Tables

Table 1. Eligibility criteria are based on the Population, Intervention, Comparison, Outcomes and Study (PICOS) elements.

Population(s)	Children and adults ¹ who are generally healthy or who have symptoms related to excessive zinc intake
Interventions, exposures	<ul style="list-style-type: none"> • Intake of zinc via supplements or foods (fortified and non-fortified) • Studies where zinc intake was not given were excluded • Studies where the effect of zinc intake could not be isolated were excluded
Comparator(s)	<ul style="list-style-type: none"> • Higher zinc intake vs lower or no zinc intake
Outcome	Adverse effects include impact on: <ul style="list-style-type: none"> • Absorption/status of other minerals (e.g. copper, iron, etc.) • Haemoglobin, ferritin • Blood lipids • Immune function • Gastrointestinal function • DNA breaks/damage
Study Designs	<ul style="list-style-type: none"> • Intervention studies assessing effects of zinc intake. Including but not limited to: RCTs, cross-over RCTs, non RCTs, pre-pots studies. • Observational studies assessing effects of zinc intake. Including but not limited to: case-control, cohort studies, cross-sectional studies • Case reports of excess zinc intake • In vitro and animal studies were not included

¹Based on results of the scoping review and related discussions, the expert group concluded that the limited data available in children aged 0-36 months may not be sufficient to identify ULs and therefore it was decided to expand the literature search to include studies in older children and adults. Data for older children and or adults will be used (i.e. extrapolated) only if data obtained via the literature for children aged 0-36 months is insufficient to identify ULs directly. RCT: randomized control trial

Table 2. Biochemical, physical, and clinical adverse effects of zinc intake in infants and children up to 3 years of age reported on the included studies

Outcome reported	Number of studies ¹	References
Biochemical outcome measures		
Hemoglobin	34 (32 ²)	(8,12,13,18,19,26,28,29,31,33–40,43,47,48,51,53,54,58,59,62,64,65,70–73) (66) ³ (52) ⁴
Hematocrit	6 (6)	(8,19,31,51,62,65)
Serum Ferritin	21 (20)	(12,18,19,26,28,29,31,34,35,39,40,47,48,51,59,70–72,74,75) (52) ³
Serum/soluble transferrin receptor (sTfR)	5 (5)	(12,28,36,47,74)
Iron deficiency	9 (9)	(12,31,34,39,47,53,59,70,71,73)
Anemia	18 (18)	(12,19,29,34,36–39,43,47,48,53–55,63,64,70,71,73)
Severe anemia	3 (3)	(12,63,64)
Iron deficiency anemia	4 (4)	(29,34,47,71,74)
Serum iron	2 (2)	(51,65)
Zn protoporphyrin (ZPP)	2 (2)	(53,74)
Plasma/serum copper	13 (13)	(51,65)
Erythrocyte SOD (eSOD)	2 (2)	(18,72)
Elevated C-Reactive Protein (CRP)	3 (3)	(36,43,70)
Lactulose:mannitol	2 (2)	(18,60)
Serum total cholesterol	3 (3)	(8,17,72)
Physical or clinical descriptive outcomes		
Vomiting	13 (0)	(8,27,30,36,41,44–46,49,50,67,69,76)
Regurgitation	5 (0)	(8,33,46,67,69)
Nausea	2 (0)	(44,45)
Constipation	4 (0)	(44,45,49,50)
Abdominal pain	3 (0)	(41,44,45)
Drowsiness	2 (0)	(44,45)
Mouth irritation	2 (0)	(44,45)
Taste aversion	3 (0)	(33,44,45)
Respiratory infection	13 (0)	(13,18,29,33,34,49,50,55,57–59,61,75)
URTI	3 (0)	(33,34,50)
Bronchiolitis	2 (0)	(33,36)
Cough	2 (0)	(29,72)
Diarrhea	27 (0)	(8,13,18,26,27,29–34,36,42–45,49,50,55,56,58,59,61,63,67,72,75)
Dysentery/bloody diarrhea	3 (0)	(36,42,55)
ORS use	2 (0)	(27,56)
Malaria	9 (0)	(18,43,55,58,63,64,70,73,74)
Fever	5 (0)	(29,34,59,72,74)
Death	7 (0)	(31,33,36,43,49,58,63)
Other	23 (0)	(8,18,20,21,31–34,36,41–45,50,51,56,62–64,68,72,74)

¹Number of studies reporting the outcome in the review (Number of studies included in meta-analysis).

²Includes 2 values converted from hematocrit. ³No SD values reported, ⁴Not included in meta-analysis as same study of Rosado et al. (59). ORS, oral rehydration solution; URTI, Upper respiratory tract infection,

Table 3. Summary of forest plot analyses of the effect of zinc supplementation intake in infants and children up to 3 years of age on hemoglobin (g/L), analyzed by duration, chemical formula, and comparator group.

Group/subgroup	References	Mean Difference	95% CI	P	I ²
Children receiving interventions for <3 months by zinc dose					
< 5 mg/d	(48)	-5.40	-24.21, 13.41		NA
5-10 mg/d	(48,73)	-5.26	-8.98, -1.54		0
10.1-20 mg/d	(51)	0.40	-3.67, 4.47		NA
Overall		-3.13	-6.82, 0.57	0.10	24
Children receiving interventions for >3 months by zinc dose					
< 5 mg/d	(8,19,34,72)	0.39	-2.70, 3.48		33
5-10 mg/d	(12,13,26,29,31,35–40,43,47,53,62,64,65,70–72)	-0.21	-1.20, 0.77		63
10.1-20 mg/d	(54,58,59)	-0.13	-1.39, 1.12		0
Zn bolus ¹	(18,28,33)	-1.24	-2.53, 0.06		0
Overall		-0.25	-1.00, 0.50	0.51	54
Children receiving zinc through zinc sulphate by zinc dose					
< 5 mg/d	(8,34,48,72)	1.82	-0.89, 4.53		0
5-10 mg/d	(12,13,26,29,35,39,40,47,48,65,71,72)	-0.97	-2.51, 0.56		66
10.1-20 mg/d	(54,58,59)	-0.03	-1.54, 1.49		0
Overall		-0.46	-1.60, 0.68	0.43	54
Children receiving zinc through zinc acetate by zinc dose					
Zn bolus ¹	(28,33)	-1.30	-2.62, 0.01		0
Overall		-1.30	-2.62, 0.01	0.05	0
Children receiving zinc through an unstated approach by zinc dose					
5-10 mg/d	(31,36,43,53,70)	0.59	-1.01, 2.18		66
10.1-20 mg/d	(54)	-0.80	-4.80, 3.20		NA
Overall		0.47	-1.01, 1.96	0.53	0
Children receiving zinc through an 'other' approach by zinc dose					
< 5 mg/d	(19)	-5.10	-10.24, 0.04		NA
10.1-20 mg/d	(59)	0.00	-2.24, 2.24		0
Overall		-1.06	-3.73, 1.62	0.44	37
Children receiving zinc versus placebo by zinc dose					
< 5 mg/d	(19,72)	-1.12	-9.70, 7.47		73
5-10 mg/d	(12,13,29,36,39,40,43,47,53,64,65,70–72)	0.25	-1.11, 1.61		52
10.1-20 mg/d	(58,59)	-0.18	-2.09, 1.73		0
Zn bolus ¹	(18,28,33)	-1.04	-2.39, 0.31		0
Overall		-0.10	-1.10, 0.90	0.84	43
Children receiving low compared to high dose zinc					
5-10 mg/d	(43,48,72)	0.35	-1.89, 2.58		0
Overall		0.35	-1.89, 2.58	0.76	0

¹Bolus doses given as follows: Brooks et al. (33) 21/d mg given weekly; Baqui et al. (28) 20 mg/d once weekly; Bates et al. (18) 70 mg/d twice weekly. CI: confidence interval, NA: not applicable

Table 4. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Anemia (odds ratio), analyzed by duration, chemical formula, and comparator group

Group/subgroup	References	Mean Difference	95% CI	P	I ²
Children receiving interventions for <3 months by zinc dose					
< 5 mg/d	(48)	4.33	0.14, 132.32		NA
5-10 mg/d	(48,73)	1.74	1.01, 2.98		0
Overall		1.78	1.04, 3.03	0.03	0
Children receiving interventions for >3 months by zinc dose					
< 5 mg/d	(19,34)	0.85	0.37, 1.95		44
5-10 mg/d	(12,29,36–39,43,47,53–55,70,71)	1.08	0.93, 1.25		30
10.1-20 mg/d	(54)	1.07	0.60, 1.90		NA
Overall		1.06	0.92, 1.22	0.43	28
Children receiving zinc through zinc gluconate by zinc dose					
5-10 mg/d	(37,38,55,73)	1.10	0.71, 1.72		41
Overall		1.10	0.71, 1.72	0.66	41
Children receiving zinc through zinc sulphate by zinc dose					
< 5 mg/d	(34,48)	0.66	0.36, 0.121		0
5-10 mg/d	(12,29,39,47,48,71)	1.28	0.98, 1.67		49
Overall		1.18	0.92, 1.53	0.19	47
Children receiving zinc through an unstated approach by zinc dose					
5-10 mg/d	(36,43,53,70)	0.97	0.81, 1.15		0
10.1-20 mg/d	(54)	1.07	0.60, 1.90		NA
Overall		0.97	0.82, 1.15	0.76	0
Children receiving zinc versus placebo by zinc dose					
< 5 mg/d	(19)	3.75	0.65, 21.74		NA
5-10 mg/d	(29,36,39,43,47,53,55,70,71)	0.89	0.75, 1.05		0
Overall		0.90	0.76, 1.06	0.21	0
Children receiving low compared to high dose zinc					
5-10 mg/d	(43,48)	1.13	0.83, 1.53		0
Overall		1.13	0.83, 1.53	0.44	0

CI: confidence interval, NA: not applicable

Table 5. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Serum ferritin ($\mu\text{g/L}$), analyzed by duration, chemical formula, and comparator group

Group/subgroup	References	Mean Difference	95% CI	P	I ²
Children receiving interventions for <3 months by zinc dose					
< 5 mg/d	(48)	-3.00	-22.84, 16.84		NA
5-10 mg/d	(48)	-3.79	-16.21, 8.63		0
10.1-20 mg/d	(51)	-0.10	-3.85, 3.65		NA
Overall		-0.49	-4.02, 3.04	0.79	0
Children receiving interventions for >3 months by zinc dose					
< 5 mg/d	(19,34)	-1.85	-9.37, 5.67		0
5-10 mg/d	(12,26,29,31,35,39,40,47,70-72,74,75)	-2.32	-5.18, -0.53		99
10.1-20 mg/d	(59)	-3.23	-8.40, 1.94		0
Zn bolus	(18,28)	3.09	-2.25, 8.43		0
Overall		-1.80	-4.31, -0.72	0.16	98
Children receiving zinc through zinc gluconate by zinc dose					
Zn bolus ¹	(18)	1.30	-5.84, 8		NA
Overall		1.30	-5.84, 8	0.72	NA
Children receiving zinc through zinc sulphate by zinc dose					
< 5 mg/d	(34,48)	-4.11	-11.95, 3.73		0
5-10 mg/d	(12,26,29,35,39,40,47,48,71,72,75)	-2.50	-6.69, 1.70		99
10.1-20 mg/d	(51)	-0.10	-3.85, 3.65		NA
Overall		-2.48	-6.30, 1.34	0.20	99
Children receiving zinc through zinc acetate by zinc dose					
10.1-20 mg/d	(28)	5.35	-2.68, 13.39		0
Overall		5.35	-2.68, 13.39	0.19	0
Children receiving zinc through an unstated approach by zinc dose					
5-10 mg/d	(31,70,74)	-0.93	-2.46, 0.61		78
Overall		-0.93	-2.46, 0.61	0.24	78
Children receiving zinc through an 'other' approach by zinc dose					
< 5 mg/d	(19)	6.65	-9.21, 22.51		NA
10.1-20 mg/d	(59)	-3.23	-8.40, 1.94		0
Overall		-2.28	-7.19, 2.63	0.36	0
Children receiving zinc versus placebo by zinc dose					
< 5 mg/d	(19)	6.65	-9.21, 22.51		NA
5-10 mg/d	(12,29,39,40,47,70-72,74,75)	-0.56	-2.35, 1.23		90
10.1-20 mg/d	(59)	-3.20	-9.33, 2.93		NA
Zn bolus ¹	(18,28)	2.75	-3.30, 8.79		0
Overall		-0.41	-2.08, 1.25	0.63	86
Children receiving low compared to high dose zinc					
5-10 mg/d	(48,74)	-8.10	-18.98, 2.78		45
Overall		-8.10	-18.98, 2.78	0.14	45

¹ Bolus doses given as follows: Baqui et al. (28) 20 mg/d once weekly; Bates et al. (18) 70 mg/d twice weekly.
CI: confidence interval, NA: not applicable

Table 6. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Serum/plasma copper concentration ($\mu\text{g/dL}$), analyzed by duration, chemical formula, and comparator group

Group/subgroup	References	Mean Difference	95% CI	P	I ²
Children receiving interventions for <3 months by zinc dose					
10.1-20 mg/d	(32)	-16.50	-24.09, -8.91		NA
>20 mg/d	(67)	0.02	-0.41, 0.45		42
Overall		-0.50	-1.90, 0.90	0.48	90
Children receiving interventions for >3 months by zinc dose					
< 5 mg/d	(8,17,34)	-4.62	-15.01, 5.78		50
5-10 mg/d	(13,35,47,62,72)	-1.50	-5.10, 2.11		0
10.1-20 mg/d	(30)	-15.50	-18.21, -12.79		NA
Zn bolus ¹	(28,33)	-1.03	-4.08, 2.01		0
Overall		-4	-8.82, 0.82	0.10	82
Children receiving zinc through zinc gluconate by zinc dose					
5-10 mg/d	(62)	-5.20	-20.16, 9.76		NA
10.1-20 mg/d	(30)	-15.50	-18.21, -12.79		NA
Overall		-13.08	-21.64, -4.53	0.003	43
Children receiving zinc through zinc sulphate by zinc dose					
< 5 mg/d	(34)	-10.25	-20.18, -0.33		0
5-10 mg/d	(8,13,35,47,72)	-0.63	-4.26, 2.99		0
10.1-20 mg/d	(32)	-16.50	-24.09, -8.91		NA
Overall		-4.09	-9.31, 1.12	0.12	61
Children receiving zinc through zinc acetate by zinc dose					
Zn bolus ¹	(28,33)	-1.03	-4.08, 2.01		0
Overall		-1.03	-4.08, 2.01	0.51	0
Children receiving zinc versus placebo by zinc dose					
< 5 mg/d	(17)	-7.52	-21.69, 6.65		NA
5-10 mg/d	(13,47,72)	-1.41	-6.76, 3.93		0
10.1-20 mg/d	(30,32)	-15.61	-18.17, -13.06		0
>20 mg/d	(67)	0.02	-0.41, 0.45		42
Zn bolus ¹	(28,33)	-0.21	-3.52, 3.09		0
Overall		-4.11	-6.48, -1.74	<0.001	94

¹ Bolus doses given as follows: Brooks et al. (33) 21/d mg given weekly; Baqui et al. (28) 20 mg/d once weekly; Bates et al. (18) 70 mg/d twice weekly. CI: confidence interval, NA: not applicable

Table 7. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Iron deficiency (odds ratio), analyzed by duration, chemical formula, and comparator group

		References	Mean Difference	95% CI	P	I ²
By treatment duration	0-3 months	(73)	0.58	0.29, 1.18		NA
	>3 months	(12,29,31,34,47,53,59,70,71)	1.02	0.77, 1.24		29
	Overall		0.98	0.77, 1.24	0.87	32
By chemical formula	Zn gluconate	(73)	0.58	0.29, 1.18		NA
	Zn sulphate	(12,29,34,47,71)	1.14	0.82, 1.60		34
	Not stated	(31,53,70)	1.04	0.80, 1.34		0
	Other	(59)	0.97	0.37, 2.53		NA
	Overall		1.01	0.83, 1.23	0.89	12
Zinc Vs Placebo		(12,29,53,59,70,71)	1.04	0.79, 1.37	0.79	13

CI: confidence interval, NA: not applicable

Table 8. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Iron deficiency anemia (odds ratio), analyzed by duration, chemical formula, and comparator group

		References	Mean Difference	95% CI	P	I ²
By treatment duration	>3 months	(29,34,39,47,71,74)	1.01	0.73, 1.39	0.97	20
By chemical formula	Zn sulphate	(29,34,39,47,71)	0.99	0.68, 1.44		34
	Not stated	(74)	1.46	0.42, 5.06		0
	Overall		1.01	0.73, 1.39	0.97	20
Zinc versus placebo		(29,39,71,74)	0.98	0.67, 1.45	0.93	20
High dose VS Low Dose		(74)	4.93	0.56, 43.27	0.15	NA

CI: confidence interval, NA: not applicable

Table 9. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Serum/soluble transferrin receptor (sTfR) (mg/L), analyzed by duration, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	>3 months	(12,28,36,47,74)	0.19	0.08, 0.29	<0.001	89
By chemical formula	Zn sulphate	(12,47)	0.18	0.07, 0.29		97
	Zn acetate	(28)	0.44	-1.08, 1.96		63
	Not stated	(36,74)	0.26	-0.13, 0.65		0
	Overall		0.19	-0.08, 0.29	<0.001	89
Zinc versus placebo and (ii) high dose versus low dose zinc		(12,28,36,47,74)	0.43	-0.16, 0.93	0.08	76
High dose VS Low Dose		(74)	-0.10	-1.19, 0.99	0.86	NA

CI: confidence interval, NA: not applicable

Table 10. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on hematocrit (proportion), analyzed by duration if intervention, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	0-3 months	(51)	-0.01	-0.04, 0.02		NA
	>3 months	(8,19,31,62,65)	0.00	-0.01, 0.01		28
	Overall		-0.00	-0.01, 0.01	0.97	17
By chemical formula	Zn gluconate	(62)	0.02	0.00, 0.03		NA
	Zn sulphate	(8,51,65)	0.00	-0.0-1, 0.01		0
	Not stated	(31)	-0.00	-0.00, 0.00		NA
	Other	(19)	-0.01	-0.02, 0.01		NA
	Overall		-0.00	-0.01, 0.01	0.97	17
Zinc Vs Placebo		(19,65)	-0.00	-0.01, 0.01	0.51	0

CI: confidence interval, NA: not applicable

Table 11. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on elevated C-Reactive Protein (CRP) (odds ratio), analyzed by duration, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	>3 months	(36,43,70)	1.19	0.91, 1.55	0.21	0
By chemical formula	Not stated	(36,43,70)	1.19	0.91, 1.55	0.21	0
Zinc Vs Placebo		(36,43)	1.05	0.74, 1.48	0.79	0
High dose VS Low Dose		(43)	0.73	0.37, 1.44	0.36	NA

CI: confidence interval, NA: not applicable

Table 12. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on serum total cholesterol (mg/dL), analyzed by duration, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	>3 months	(8,17,72)	-0.79	-6.24, 4.66	0.78	0
By chemical formula	Zn sulphate	(8,72)	-1.73	-7.70, 4.23		0
	Other	(17)	4.00	-9.45, 17.45		NA
	Overall		0.79	-6.24, 4.66	0.78	0
Zinc Vs Placebo		(17,72)	-1.07	-6.82, 4.69	0.72	0

CI: confidence interval, NA: not applicable

Table 13. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on Lactulose:Mannitol molar ratio, analyzed by duration, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	0-3 months	(60)	-0.08	-0.15, -0.01		NA
	>3 months	(18)	-0.10	-0.27, 0.07		NA
	Overall		-0.08	-0.14, -0.02	<0.001	0
By chemical formula	Zn gluconate	(18)	-0.10	-0.27, 0.07		NA
	Zn acetate	(60)	-0.08	-0.15, -0.01		NA
	Overall		-0.08	-0.14, -0.12	<0.001	0
Zinc Vs Placebo		(18,60)	-0.08	-0.14, 0.02	0.009	0

CI: confidence interval, NA: not applicable

Table 14. Summary of forest plot analyses of the effect of zinc supplementation in infants and children up to 3 years of age on serum iron concentration ($\mu\text{g/dL}$), analyzed by duration, chemical formula, and comparator group.

		References	Mean Difference	95% CI	P	I ²
By treatment duration	0-3 months	(51)	-0.12	-11.16, 10.92		NA
	>3 months	(65)	12.50	10.37, 14.63		NA
	Overall		7.40	-4.74, 19.54	0.23	79
By chemical formula	Zn sulphate	(51,65)	7.40	-4.74, 19.54	0.23	79
Zinc Vs Placebo		(65)	12.50	10.37, 14.63	<0.001	NA

CI: confidence interval, NA: not applicable

Figures




Figure 1. PRISMA-2020 flow diagram of the search procedure. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Note: ¹ See supplementary file 2 for further information on how studies were selected.




Figure 2. Effect of zinc supplementation on hemoglobin (g/L) in children aged 0-90 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 3. Effect of zinc supplementation on hemoglobin (g/L) in children aged 91-180 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 4. Effect of zinc supplementation on hemoglobin (g/L) in children aged over 6 months to 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 5. Effect of zinc supplementation on hemoglobin (g/L) in children aged over 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 6. Effect of zinc supplementation on anemia (OR) in children aged 91-180 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 7. Effect of zinc supplementation on anemia (OR) in children aged over 6 months to 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 8. Effect of zinc supplementation on anemia (OR) in children aged over 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 9. Effect of zinc supplementation on serum ferritin ($\mu\text{g/L}$) in children aged 0-90 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 10. Effect of zinc supplementation on serum ferritin ($\mu\text{g/L}$) in children aged 91-180 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 11. Effect of zinc supplementation on serum ferritin ($\mu\text{g/L}$) in children aged over 6 months to 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 12. Effect of zinc supplementation on serum ferritin ($\mu\text{g/L}$) in children aged over 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 13. Effect of zinc supplementation on serum/plasma copper ($\mu\text{g/dL}$) in children aged 91-180 days by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 14. Effect of zinc supplementation on serum/plasma copper ($\mu\text{g/dL}$) in children aged over 6 months to 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 15. Effect of zinc supplementation on serum/plasma copper ($\mu\text{g/dL}$) in children aged over 12 months by zinc dose

Note: CI: confidence interval, SD: standard deviation.




Figure 16. Effect of zinc supplementation in infants and children up to 3 years of age on iron deficiency (OR) by age group

Note: Zinc exposure corresponds to mg/d except for Rosado et al. (59) for which doses were given 6 days a week. CI: confidence interval, SD: standard deviation.




Figure 17. Effect of zinc supplementation in infants and children up to 3 years of age on iron deficiency anemia (OR) by age group

Note: Zinc exposure corresponds to mg/d. CI: confidence interval, SD: standard deviation.




Figure 18. Effect of zinc supplementation in infants and children up to 3 years of age on serum/soluble transferrin receptor (mg/L) by age group

Note: Zinc exposure corresponds to mg/d except for Baqui et al. (28) for which dose was 20 mg/d once weekly, Chang et al. (36) for which dose was given in alternate days. CI: confidence interval, SD: standard deviation.




Figure 19. Effect of zinc supplementation in infants and children up to 3 years of age on hematocrit (proportion) by age group

Note: Zinc exposure corresponds to mg/d. CI: confidence interval, SD: standard deviation.




Figure 20. Effect of zinc supplementation in infants and children up to 3 years of age on raised CRP by age group

Note: Zinc exposure corresponds to mg/d except for Chang et al. (36) for which dose was given in alternate days. CI: confidence interval, SD: standard deviation.




Figure 21. Effect of zinc supplementation on erythrocyte SOD (IU/mg Hb) in children aged over 12 months by zinc dose

Note: Zinc exposure corresponds to mg/d. CI: confidence interval, SD: standard deviation.




Figure 22. Effect of zinc supplementation on zinc Protoporphyrin ($\mu\text{mol/mol}$ heme) in children over 6 months to 12 months by zinc dose

Note: Zinc exposure corresponds to mg/d. CI: confidence interval, SD: standard deviation.




Figure 23. Effect of zinc supplementation in infants and children up to 3 years of age on serum total cholesterol (mg/dL) by duration of treatment

Note: Zinc exposure corresponds to mg/d except for Hambidge et al. (17) for which doses were given 6 days a week. CI: confidence interval, SD: standard deviation.




Figure 24. Effect of zinc supplementation in infants and children up to 3 years of age on lactulose mannitol by age group

Note: Zinc exposure corresponds to mg/d except for Bates et al. (18) for which doses of 70 mg/d were given twice weekly. CI: confidence interval, SD: standard deviation.




Figure 25. Effect of zinc supplementation in infants and children up to 3 years of age on serum Iron Concentration ($\mu\text{g/dL}$) by age group

Note: CI: confidence interval, SD: standard deviation.